Evolus, Inc. (EOLS)
Healthcare
- Fundamental
- 3
- Sentiment
- 4
- Technical
- 3
Buy limit 7.80 GTC on the pullback-to-support base (7.75 swing low) within an intact uptrend above SMA50/SMA200; protective stop 7.39 (Change-A pullback ATR floor = 1.0xATR below entry); targets 8.62 (SMA20 zone) and 9.24; R/R 2.00; no earnings/dividend/split event inside the ±3-day entry window or the 15-trading-day horizon.
Company overview
Evolus, Inc. is a performance beauty company providing medical aesthetic solutions in the U.S. Its main product, Jeuveau, is a botulinum toxin type A formulation for smoothing frown lines in adults. The company is headquartered in Newport Beach, California.
Fundamental
fairEvolus shows strong revenue growth but remains GAAP unprofitable with cash burn and leverage risks.
Mixed setup: revenue has grown strongly over the last five years and recent quarters show continued momentum, but GAAP profitability and cash generation remain negative. Liquidity appears adequate over the next year per recent SEC filings, yet leverage and interest expense amplify risk until earnings and cash flow turn sustainably positive.
Sentiment
goodMedia and analyst sentiment is positive following strong earnings and raised guidance.
Q2 results and a raised full-year outlook (announced 2026-08-05) are the dominant near-term driver, and last ~14d media tone is net bullish. Baseline sentiment 30–90d is also bullish, implying a largely stable narrative (polarity_score ~+0.34 vs ~+0.43), while Reddit signal is effectively absent; Red-Flag Screen clean based on available scans.
Technical
fairThe stock is stabilizing above key moving averages after a pullback, with oversold momentum indicators.
Mixed read: EOLS has pulled back ~15% from its 9.30 high into a 7.75–7.86 three-session stabilization shelf that sits above a rising SMA50 (7.39) and SMA200 (6.09), keeping the longer-term uptrend intact, and the MACD line remains positive (0.22). Against that, the short-term stack is broken — price is below SMA20 (8.61), EMA9 (8.40), EMA21 (8.32) and the daily VWAP (8.01) — RSI14 is 45.17 and below 50, the MACD histogram is negative and widening (-0.21), and ADX 51 mostly measures the strength of the current down leg. Bullish offsets: Williams %R at -88.46 (oversold), three consecutive higher daily lows (7.75/7.81/7.86), Monday's first green close on the lightest volume of the pullback, and contracting volume into the decline. Net: a stabilization attempt within an uptrend, not yet a confirmed reversal — mixed, score 3.
You’re looking at 2026-09-14 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

